|
Monday, March 15, 8:00 AM to 9:30 AM
Who doesn’t love the “pearls and pitfalls” sessions? These are one of the best ways to get to the “heart” of a topic.
It was just a few years ago that papers were appearing describing the successful ablation of idiopathic outflow tract ventricular tachycardia from the distal great cardiac vein rather than the aortic cusp. While this might give EPs another option for treatment protocol, it’s still important to understand the challenges associated with the aortic valve cusp approach. That is just one of the topics that will be discussed in this session.
The FDA has approved Sorin Group’s next-generation cardiac resynchronization therapy defibrillator (CRT-D), the Paradym CRT Model 8750.
Cardima, a medical device company, has received regulatory approval from the Japanese Ministry of Health, Labor and Welfare for its guidewire-based, multi-electrode diagnostic mapping catheter, Pathfinder.
Research presented at the 2009 American Heart Association (AHA) scientific sessions in Orlando based on the subanalysis from the ADMIRE-HF phase III clinical trial suggested that imaging of the cardiac sympathetic nerves using the molecular imaging agent 123I-meta-iodobenzylguanidine (123I-MIBG, AdreView; GE Healthcare) may be useful in the assessment of risk for cardiac arrhythmias and cardiac death.
Prophylactic implantable cardioverter-defibrillator (ICD) therapy did not reduce overall mortality among patients with acute MI and clinical features that placed them at increased risk, according to the randomized, prospective IRIS trial published Thursday in the New England Journal of Medicine.
The chance that a person in cardiac arrest will survive increases when rescuers doing cardiopulmonary resuscitation (CPR) spend more time giving chest compressions, according to a multi-center study reported Sept. 14 in Circulation.
The FDA has approved Biosense Webster's Navistar RMT ThermoCool catheter for use in operations to eliminate abnormal heart rhythms.
While Scottish mystery writer Sir Arthur Conan Doyle metaphorically refers to the emotional pleasantries so often linked to the myocardium, this week physicians and regulators have made strides for treating atrial fibrillation (a-fib), a condition in which fluctuations in the heart can prove deadly.
The FDA has granted marketing approval to Biosense Webster's NaviStar ThermoCool Catheter for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation (a-fib), when used with compatible 3D electroanatomic mapping systems.
|
March 14, Sunday 2:30 PM to 3:30 PM
Ventricular tachycardia that lasts at least 30 seconds is termed sustained VT. It generally requires termination by anti-arrhythmia drugs, anti-tachycardia pacing techniques or electrical cardioversion. The most commonly used drugs are amiodarone, lidocaine and procainamide.
Sustained VT can occur in conjunction with some other cardiac dysfunction such as ischemic MI and the patient can be hemodynamically stable or unstable. How do EPs determine the best course of treatment?
Bioniche Pharma, a developer of injectable pharmaceuticals, has launched ibutilide fumarate injection, the generic equivalent of Pfizer's antiarrhythmic drug Corvert .
Patients with episodes of ventricular tachycardia (VT) are at high risk of repeat VT, ventricular fibrillation and death; and the use of an implantable cardioverter-defibrillator (ICD) reduces mortality compared with drug treatment for VT. The VTACH study, published Dec. 31 in the Lancet, shows that use of catheter ablation prior to ICD implantation reduces the risk of VT recurrence at two years.
Orlando, Fla.—Targeted postmortem testing to identify genetic mutations associated with sudden unexplained death (SUD) is an effective and less expensive way to determine risk to relatives than comprehensive cardiac testing of first-degree relatives, according to a study presented Sunday at the 2009 American Heart Association scientific sessions. The researchers also called for more health insurance coverage for these tests.
The use of contrast agents during stress echocardiography does not lead to short- or long-term risk of death or myocardial infarction, according to a study in the September issue of the Journal of the American College of Cardiology: Cardiovascular Imaging.
CardioNet has released clinical and reporting enhancements to its existing Mobile Cardiac Outpatient Telemetry service.
A new study in the journal HeartRhythm reveals that the potential of Sprint Fidelis lead failure increases, mainly due to the device's "fatigue mechanism," while the failure rates of other defibrillator leads are low and stable, lead researcher Robert G. Hauser, MD, told Cardiovascular Business News.
Transoma Medical, a manufacturer of automated implantable cardiac monitoring systems, received FDA marketing clearance on a second-generation product, Sleuth Advanced Trending cardiac monitoring system.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).